Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Bayer Plans $138 Million Expansion of Beijing Facility

publication date: Mar 31, 2014
Bayer HealthCare will invest $138 million to expand its Beijing manufacturing facility. The plant is expected to meet growing demand for Bayer’s healthcare offerings, including products in the cardiovascular and diabetes sector. The expanded facility will house logistics areas for fully automated material handling, analytical laboratories and high-speed packaging lines. China is high on Bayer’s investment list. One month ago, it purchased Dihon Pharmaceutical Group, a TCM/over-the-counter drug maker. Although the price was undisclosed, it was thought to be around $680 million. More details....

Stock Symbol: (XETRA: BAYN)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital